American Society of Hirudotherapy

Anticoagulation management of patients with long-term warfarin therapy after valve replacement during the perioperative period of pacemaker implantation.

Research article published in International journal of clinical and experimental medicine (2013)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportClinical TrialsHan et al. · International journal of clinical and experimental medicine, 2013

Abstract

BACKGROUND: To explore an optimal management of perioperative anticoagulation for patients with long-term warfarin therapy after valve replacement during the perioperative of pacemaker implantation. METHODS: We retrospectively reviewed consecutive patients undergoing pacemaker implantation who received long-term warfarin therapy after valve replacements at our hospital. They were divided into 3 groups: discontinued group, bridging group and continued group. We analyzed the relationship between different anticoagulation methods during the peri-procedure period and hemorrhage and embolism events. RESULTS: 132 patients were enrolled. There was no significant difference concerning the mean age, sex, concomitant diseases, atrial fibrillation and whether performed pacemaker replacement among 3 groups. The incidence of hematomas was irrespective of the perioperative anticoagulation strategy used (P = 0.125). A strategy involving bridging anticoagulation with therapeutic-dose heparin was associated with an incidence of wound errhysis (P = 0.008). There was no thromboembolism event in these three groups. CONCLUSION: The results showed that there was no significant difference in hematoma rate among continued group, discontinued group, and bridging group, but there was much more wound errhysis in the bridging group. Also, the study shows that if warfarin is continued, it will not increase the risk of bleeding when the International Normalized Ratio (INR) is around 1.7 during the procedure.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Summary

Anticoagulation management of patients with long-term warfarin therapy after valve replacement during the perioperative period of pacemaker implantation.

Why This Matters for Hirudotherapy

This retrospective study compared three perioperative anticoagulation strategies (discontinued, bridging with heparin, and continued warfarin) in 132 long-term warfarin patients undergoing pacemaker implantation after valve replacement, finding no significant difference in hematoma rates but more wound errhysis in the bridging group and no thromboembolic events. The abstract addresses pharmaceutical anticoagulant management around device implantation and contains no reference to leeches, hirudotherapy, hirudin, or any leech-derived substance. There is no defensible relevance to ASH's domain.

Citation

Anticoagulation management of patients with long-term warfarin therapy after valve replacement during the perioperative period of pacemaker implantation.

Han et al. · International journal of clinical and experimental medicine, 2013

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.